474 assets in Plasma Cell Myeloma

Therapeutic assets addressing Plasma Cell Myeloma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Autologous Bcma/Gprc5D Dual-Target Car-T Plasma Cell Myeloma	Beijing Biotech	P1/2	CC (47)
Autologous Cd19/Cd20 Dual-Target Car-T Module Plasma Cell Myeloma	Beijing Biotech	P1/2	CC (47)
Autologous Cd19/Cd22 Dual-Target Car-T Module Plasma Cell Myeloma	Beijing Biotech	P1/2	CC (47)
Autologous Cd33/Cd123 Dual-Target Car-T Module Plasma Cell Myeloma	Beijing Biotech	P1/2	CC (47)
Autologous Cd33/Cll1 Dual-Target Car-T Module Plasma Cell Myeloma	Beijing Biotech	P1/2	CC (47)
Autologous Cd5/Cd7 Dual-Target Car-T Module Plasma Cell Myeloma	Beijing Biotech	P1/2	CC (47)
Moderna Covid-19 Vaccine Rna Plasma Cell Myeloma	Barbara Ann Karmanos Cancer Institute	P2	CC (47)
Bms-986345 Plasma Cell Myeloma	H. Lee Moffitt Cancer Center and Research Institute	P1	CC (46)
Descartes-08 Plasma Cell Myeloma	Cartesian Therapeutics	P2	CC (46)
Duvelisib Plasma Cell Myeloma	H. Lee Moffitt Cancer Center and Research Institute	P1	CC (46)
Fexagratinib Plasma Cell Myeloma	National Cancer Institute (NCI)	P2	CC (46)
Ganciclovir Plasma Cell Myeloma	City of Hope Medical Center	P2	CC (46)
Gpc-100 Plasma Cell Myeloma	GPCR Therapeutics, Inc.	P2	CC (46)
phe885 Plasma Cell Myeloma	Novartis Pharmaceuticals	P2	CC (46)
Universal Donor Expanded Tgf-Beta-Imprinted Nk Cells Plasma Cell Myeloma	Elvira Umyarova	P1	CC (46)
Abbv-453 Plasma Cell Myeloma	AbbVie	P1/2	CC (45)
Binimetinib Plasma Cell Myeloma	University of Heidelberg Medical Center	P2	CC (45)
bt02 Plasma Cell Myeloma	Biotroy Therapeutics	P1/2	CC (45)
Fully Human Bcma Chimeric Antigen Receptor Autologous T Cell Plasma Cell Myeloma	Nanjing IASO Biotechnology Co., Ltd.	P1/2	CC (45)
Gic-102 Plasma Cell Myeloma	GI Cell, Inc.	P1/2	CC (45)
Hdp-101 Plasma Cell Myeloma	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.	P1/2	CC (45)
Idp-121 Plasma Cell Myeloma	IDP Discovery Pharma S.L.	P1/2	CC (45)
Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Cd38 (Adp-Ribosyl Cyclase 1, Cyclic Adp-Ribose Hydrolase 1, Cadpr Hydrolase 1, Cadpr1)], Humanized Monoclonal Antibody Plasma Cell Myeloma	Keymed Biosciences Co.Ltd	P1/2	CC (45)
Isb 1442 Plasma Cell Myeloma	Ichnos Sciences SA	P1/2	CC (45)
Lbl-034 For Plasma Cell Myeloma	Nanjing Leads Biolabs Co.,Ltd	P1/2	CC (45)
lm-305 Plasma Cell Myeloma	LaNova Medicines Limited	P1/2	CC (45)
mbs314 Plasma Cell Myeloma	Beijing Mabworks Biotech Co., Ltd.	P1/2	CC (45)
Melphalan Flufenamide Plasma Cell Myeloma	Fondazione EMN Italy Onlus	P3	CC (45)
Mrna-2808 Plasma Cell Myeloma	ModernaTX, Inc.	P1/2	CC (45)
Nirogacestat Plasma Cell Myeloma	Hellenic Society of Hematology	P2	CC (45)
Opc-415 Plasma Cell Myeloma	Otsuka Pharmaceutical Co., Ltd.	P1/2	CC (45)
Oricar-017 Plasma Cell Myeloma	OriCell Therapeutics Co., Ltd.	P1/2	CC (45)
Regn7945 Plasma Cell Myeloma	Regeneron Pharmaceuticals	P1/2	CC (45)
Sonrotoclax Plasma Cell Myeloma	BeOne Medicines	P1/2	CC (45)
ibi346 Plasma Cell Myeloma	Chunrui Li	P1	CC (44)
Oric-533 Free Base Plasma Cell Myeloma	ORIC Pharmaceuticals	P1	CC (44)
18f-flt Plasma Cell Myeloma	University of Oklahoma	P1	CC (43)
Actinium Ac 225-Dota-Daratumumab Plasma Cell Myeloma	City of Hope Medical Center	P1	CC (43)
Anti-Bcma-Car-T Plasma Cell Myeloma	Institute of Hematology & Blood Diseases Hospital, China	P2	CC (43)
Auto Car T Cell Therapy Plasma Cell Myeloma	Autolus Limited	P2	CC (43)
Autologous Car-T Cell Therapy Expressing The Baff-Ligand. Plasma Cell Myeloma	Luminary Therapeutics	P1	CC (43)
Autologous Muc1-Activated T-Cells Plasma Cell Myeloma	Mayo Clinic	P1	CC (43)
Axitinib Plasma Cell Myeloma	Canadian Cancer Trials Group	P2	CC (43)
AXUMIN Plasma Cell Myeloma	National Cancer Institute (NCI)	P2	CC (43)
Bcma-Cd19 Ccar T Cells Plasma Cell Myeloma	Beijing GoBroad Hospital	P1	CC (43)
Budesonide Plasma Cell Myeloma	University of Utah	P2	CC (43)
Capivasertib Plasma Cell Myeloma	National Cancer Institute (NCI)	P2	CC (43)
Cellprotect Plasma Cell Myeloma	Karolinska Institutet	P2	CC (43)
Copanlisib Plasma Cell Myeloma	OHSU Knight Cancer Institute	P2	CC (43)
Cyad-211 Plasma Cell Myeloma	Celyad Oncology SA	P1	CC (43)

Showing 201 to 250 of 474 assets

PreviousPage 5 of 10Next